Subtype
High-Grade Glioma, NOS
CI-CAN-00009391Explore in graph →
75 active trials2 approved drugs11 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009391Explore in graph →
Clinical trials
173 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (30)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04552756 | Seizures During Radiotherapy for High-grade Gliomas(SURF-ROGG) | terminated | N/A | 23 | University Hospital Schleswig-HolsteinOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06737146 | Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma | not yet recruiting | Phase 1 | 12 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06736470 | Surgical Suction Aspirates Fluorescence Measurement(ATM GBM) | recruiting | — | 25 | Kuopio University HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT04267146 | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma(NIVOGLIO) | completed | Phase 1 / Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06161610 | Recurrent High Grade Glioma Treated by LITT(REGALITT) | recruiting | N/A | 135 | Beijing Tiantan HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | terminated | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03294434 | Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)(PRaM-GBM) | completed | — | 147 | CCTU- Cancer ThemeOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | withdrawn | Phase 1 | 0 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 0 | Jun 6, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma(BrTK02) | completed | Phase 2 | 52 | Candel Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03925246 | Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas(REVOLUMAB) | completed | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06215495 | A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial | recruiting | N/A | 88 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | recruiting | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06201351 | Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI | not yet recruiting | — | 60 | West China HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | terminated | Phase 1 / Phase 2 | 8 | Institut CurieOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03458312 | Nurse-led Family and Network Consultations(CARES) | completed | N/A | 114 | Rigshospitalet, DenmarkOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03425292 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | completed | Phase 1 | 49 | Saint John's Cancer InstituteOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT02575794 | Terameprocol in Treating Patients With Recurrent High Grade Glioma | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05873946 | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery(2D-ioUS-Glio) | completed | — | 99 | Hospital del Rio HortegaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | terminated | Phase 1 | 7 | OncoSynergy, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT01466686 | Low Dose Radiation Therapy for Glioblastoma Multiforme | completed | Phase 2 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05929456 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)(MIRROR) | unknown | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02022644 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | completed | Phase 1 | 18 | University of California, San FranciscoOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03411408 | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.(HBO-RT) | unknown | N/A | 24 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05850377 | 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | unknown | — | 90 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT03355794 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | completed | Phase 1 | 19 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT04908267 | How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas | unknown | — | 100 | Weiguo ZhangOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05630664 | Liquid Biopsy in High-grade Gliomas and Meningiomas(SOPRANO) | unknown | — | 90 | IRCCS San RaffaeleOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | terminated | Phase 2 | 4 | Indiana UniversityOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03352427 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | terminated | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02567539 | Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma | completed | N/A | 88 | Istituto Clinico HumanitasOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | completed | Phase 1 | 20 | Macarena De La Fuente, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03775369 | Glioma and Exercising | completed | N/A | 39 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01222754 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2022 | clinicaltrials |
| NCT01729260 | Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide(Mebendazole) | completed | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04822805 | A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma | unknown | Phase 2 | 27 | First People's Hospital of HangzhouOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04588987 | Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02239952 | HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) | unknown | N/A | 15 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01390948 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 14 | Aug 6, 2020 | clinicaltrials |
| NCT04220892 | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | withdrawn | Early Phase 1 | 0 | Jose CarrilloOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care(Toca7) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT01403610 | Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab | completed | Phase 2 | 28 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 24, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 15, 2025source: clinicaltrials